Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lusedra
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Lusedra (fospropofol disodium) is an intravenous sedative-hypnotic agent developed by Eisai Inc. for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. It is a water-soluble prodrug of propofol, which is released following hydrolysis by alkaline phosphatase enzymes in the body. Once converted, the active metabolite propofol acts as a positive allosteric modulator of GABA-A receptors in the central nervous system, enhancing inhibitory neurotransmission to produce sedation and hypnosis. Lusedra was approved by the FDA in December 2008 and is classified as a Schedule IV controlled substance. Compared to traditional lipid-emulsion propofol, Lusedra offers a different pharmacokinetic profile with a slower onset and longer duration of action, and it does not require the lipid vehicle that can be associated with pain on injection or hyperlipidemia.
- Brand names
- Lusedra
- Other names
- fospropofol disodiumfospropofolpropofol phosphate
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on Lusedra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lusedra.